Dual GLP-1/GIP receptor agonist that outperforms semaglutide in head-to-head trials. Up to 22.5% body weight reduction in Phase III — the highest of any peptide therapy.
Tirzepatide is a dual incretin agonist that activates both GLP-1 and GIP receptors simultaneously. This dual mechanism provides enhanced appetite suppression, improved insulin sensitivity, and greater weight loss compared to GLP-1-only agonists. The GIP component adds metabolic benefits including improved lipid metabolism and potentially better preservation of lean mass during weight loss.
The SURMOUNT trials enrolled substantial female populations and demonstrated consistent efficacy across genders. For women with PCOS-related insulin resistance, the dual mechanism may offer advantages over GLP-1-only therapy. The superior weight loss efficacy (22.5% vs 15-17% for semaglutide) is particularly relevant for menopausal women facing metabolic-shift-driven weight gain that is resistant to lifestyle intervention alone.
Similar GI side effect profile to semaglutide: nausea (most common, especially during titration), vomiting, diarrhea, constipation. Generally improves with dose stabilization. Same boxed warning regarding thyroid C-cell tumors (animal data). Contraindicated with personal/family history of medullary thyroid carcinoma.
In head-to-head trials (SURPASS-2), tirzepatide produced greater weight loss and HbA1c reduction than semaglutide at comparable doses. However, individual response varies and the best choice depends on your specific health profile and provider guidance.
Tirzepatide improves insulin sensitivity through dual GLP-1/GIP agonism, which directly addresses the insulin resistance underlying PCOS. While not FDA-approved for PCOS specifically, the metabolic benefits are mechanistically relevant.
Part of our Weight Management hub.
Medical Disclaimer: This profile is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide therapy.
Affiliate Disclosure: Vendor links are affiliate partnerships. Full disclosure →
Take our 60-second quiz for a personalized recommendation.
Find Your Peptide →